The $100 Billion Surgery Giant That Wall Street Suddenly Doesn't Trust
Intuitive Surgical reported Q2 adjusted EPS of $2.80 vs $2.50 expected and revenue of $2.89B vs $2.82B, with 468 new da Vinci systems installed and an installed base of 11,710. Shares fell over 9% after-hours and trade near the 52-week low. Guidance for 2026 was confirmed but not raised, while analysts cited ACA subsidy changes, GLP-1 impacts, and tariffs.
How this was made
The 30-second read
Why it matters
Despite beating EPS and revenue, the stock sold off because management confirmed the 2026 growth target without raising it, while investors weighed policy, drug-substitution, and tariff headwinds.
Market read
Traders should focus on whether unchanged guidance and macro headwinds justify further multiple compression, even with an earnings beat and continued da Vinci 5 placements.
What to watch
The article notes an AI framework unveiling and a large installed base; if adoption improves procedure economics, the market’s focus on macro could overstate fundamental deterioration.
Background
ISRG is a near-monopoly provider of da Vinci robotic surgery systems, and the article frames a widening gap between operational results and market expectations.
Ticker impact
Intuitive Surgical reported Q2 EPS of $2.80 and revenue of $2.89B, but shares fell over 9% after-hours and guidance was not raised.
Near-term downside risk remains elevated while investors focus on whether procedure demand slows further under policy and tariff uncertainty.
The article ties the immediate post-earnings drop to guidance not being increased and highlights specific demand/cost pressures that could affect future procedure volumes and margins.
Market effects
Medtech and surgical-robotics sentiment may weaken if elective procedure demand is pressured by insurance coverage changes and GLP-1 substitution.
Tariff-driven component cost pressure is framed as affecting endoscopes manufactured in Germany, potentially influencing broader medtech supply-chain pricing.
If U.S. healthcare policy and trade costs persist, global procedure growth expectations for robotic surgery could be repriced.
Counterpoint
The operating business is described as intact, with revenue growth and da Vinci 5 placements supporting a longer-term thesis despite near-term macro noise.
Key entities
- companyIntuitive Surgical
Reported Q2 results, confirmed 2026 growth target without raising it, and unveiled an AI framework at a robotic surgery conference.
- analyst_firmBernstein
Cut its price target from $750 to $685 while maintaining a positive rating.
- analyst_firmStifel
Slashed its price target from $670 to $550 while maintaining a positive rating.
- analyst_firmBMO Capital
Kept an Outperform rating and a $518 target.
- companyHCA Healthcare
Warned about softening surgical demand tied to ACA subsidy dynamics, cited as read-across.
%252FIntuitive%252520Surgical%252520Inc%252520location%252520sign-by%252520Sundry%252520Photography%252520via%252520iStock.jpg&w=3840&q=75)